Article

Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Center for Biomedical Research, HIV/AIDS Program, Population Council, New York, NY, USA.
JAIDS Journal of Acquired Immune Deficiency Syndromes (Impact Factor: 4.39). 09/2009; 52(4):433-42. DOI: 10.1097/QAI.0b013e3181b880f3
Source: PubMed

ABSTRACT Although mucosal responses are important for preventing infections with HIV, the optimal strategies for inducing them remain unclear. To evaluate vaccine strategies targeting the oral mucosal lymphoid tissue inductive sites as an approach to provide immunity at distal sites, we vaccinated healthy macaques via the palatine/lingual tonsils with aldrithiol 2 (AT-2) inactivated Simian immunodeficiency virus (SIV)mac239, combined with CpG-C immunostimulatory oligonucleotide (CpG-C ISS-ODN, C274) as the adjuvant.
Macaques received 5 doses of C274 or control ODN C661 and AT-2 SIV on the tonsillar tissues every 6 weeks before being challenged rectally with SIVmac239, 8 weeks after the last immunization.
Although no T-cell or B-cell responses were detected in the blood before challenge, antibody (Ab) responses were detected in the rectum. Immunization with AT-2 SIV significantly reduced the frequency of infection compared with nonimmunized controls, irrespective of adjuvant. In the vaccinated animals that became infected, peak viremias were somewhat reduced. SIV-specific responses were detected in the blood once animals became infected with no detectable differences between the differently immunized groups and the controls.
This work provides evidence that vaccine immunogens applied to the oral mucosal associated lymphoid tissues can provide benefit against rectal challenge, a finding with important implications for mucosal vaccination strategies.

0 Followers
 · 
113 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An efficacious HIV vaccine is urgently needed to curb the AIDS pandemic. The modest protection elicited in the phase III clinical vaccine trial in Thailand provided hope that this goal might be achieved. However, new approaches are necessary for further advances. As HIV is transmitted primarily across mucosal surfaces, development of immunity at these sites is critical, but few clinical vaccine trials have targeted these sites or assessed vaccine-elicited mucosal immune responses. Pre-clinical studies in non-human primate models have facilitated progress in mucosal vaccine development by evaluating candidate vaccine approaches, developing methodologies for collecting and assessing mucosal samples, and providing clues to immune correlates of protective immunity for further investigation. In this review we have focused on non-human primate studies which have provided important information for future design of vaccine strategies, targeting of mucosal inductive sites, and assessment of mucosal immunity. Knowledge gained in these studies will inform mucosal vaccine design and evaluation in human clinical trials.
    Viruses 08/2014; 6(8):3129-3158. DOI:10.3390/v6083129 · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract CD4(+) T cells in the mucosa of the gastrointestinal (GI) tract are preferentially targeted and depleted by HIV. As such, the induction of an effective anti-HIV immune response in the mucosa of the GI tract-through vaccination-could protect this vulnerable population of cells. Mucosal vaccination provides a promising means of inducing robust humoral and cellular responses in the GI tract. Here we review data from the literature about the effectiveness of various mucosal vaccination routes-oral (intraintestinal/tonsilar/sublingual), intranasal, and intrarectal-with regard to the induction of immune responses mediated by cytotoxic T cells and antibodies in the GI mucosa, as well as protective efficacy in challenge models. We present data from the literature indicating that mucosal routes have the potential to effectively elicit GI mucosal immunity and protect against challenge. Given their capacity for the induction of anti-HIV immune responses in the GI mucosa, we propose that mucosal routes, including the nonconventional sublingual, tonsilar, and intrarectal routes, be considered for the delivery of the next generation HIV vaccines. However, further studies are necessary to determine the ideal vectors and vaccination regimens for these routes of immunization and to validate their efficacy in controlling HIV infection.
    AIDS Research and Human Retroviruses 11/2014; 30(11):1027-40. DOI:10.1089/aid.2014.0233 · 2.46 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Route of vaccine administration plays an important role in the development of immune response. Antigen administered via different anatomical sites interacts with diverse subsets of antigen presenting cells. Diverse population of antigen presenting cells directs a drastically different immune response. Initially, the recommended routes for vaccine administration were also selected on the basis of clinical trials conducted for the drug molecules. However, physicochemical and pharmaceutical behaviors of proteins (antigens) and chemical compounds are entirely different. Most of the commercial vaccines are injected in the arm or in the scapular region (deltoid muscle). Vaccine administered to these conventional anatomical sites has failed to induce desired immune response due to lack of optimum level of antigen presenting cells. In this review, we have discussed the importance of the selection of anatomical sites for vaccine administration. Mere selection of an optimum site for vaccine administration may drastically change the immune response of the current marketed formulations without any alteration in their existing production plans.
    International immunopharmacology 01/2014; DOI:10.1016/j.intimp.2013.12.023 · 2.71 Impact Factor

Full-text (2 Sources)

Download
65 Downloads
Available from
May 28, 2014